Exclusive: AstraZeneca’s outgoing R&D chief Mene Pangalos reflects on a 14-year R&D turnaround and the industry's future

When AstraZeneca R&D executive Mene Pangalos joined the company in 2010, the UK drug giant was facing existential threats: shrinking sales, a meek pipeline and a takeover attempt by Pfizer.

Pangalos saw the biggest problem: AstraZeneca’s research wasn’t delivering. AstraZeneca had a 4% success rate in bringing drugs through Phase III, trailing a 6% industry average. He pushed a new focus on quality over quantity that, from 2012 to 2016, drove AstraZeneca’s success rate to 19% — even as the industry average fell to 4%.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。